Abstract
We will develop tissue-engineered complex model systems in 3D, which contain distinct cell populations, modelling complex tissues. We will use these to evaluate action of nano-targeted agents directed against critical pathways controlling cell growth and proliferation.
Incorporating immune cells is the key innovation for this model. Cancer progression within the complex milieu will be interrogated at the tissue, cell and genetic level.
New generation biologics, acting directly against cancer cells and indirectly by recruiting immune cells, will be tested in immunocompetent models. Novel biologic-nanoparticle conjugates serving as dual imaging/therapeutic agents will map drug-cell interactions and drug fate within tissues.
References
1Moreno-Moral A et al., Changes in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution to disease risk. Ann Rheum Dis 2018 Jan. In Press
3Taher T et al., Defective regulation of autoreactive IL-6 producing transitional B cells is associated with disease in patients with systemic sclerosis. Arthritis Rheumatol 2017 Nov 28. [Epub ahead of print]
Magdeldin T et al., Engineering a vascularised 3D in vitro model of cancer progression. Scientific Reports 2017 doi:10.1038/srep44045
Ramesh BS et al., Detection of Cell Surface Calreticulin as a Potential Cancer Biomarker Using Near-Infrared Emitting Gold Nanoclusters. Nanotech 2016 27(28):285101. doi: 10.1088/0957-4484/27/28/285101.
Lopez-Davila V et al., Efficacy of DOPE/DC-cholesterol liposomes and GCPQ micelles as AZD6244 nanocarriers in a 3D colorectal cancer in vitro model. Nanomedicine 2016 11(4), 331-44, doi: 10.2217/nnm.15.206.